Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 45 | 4,820 | 47% |
| 2020 | 35 | 4,009 | 49% |
| 2021 | 43 | 4,279 | 51% |
| 2022 | 36 | 4,236 | 53% |
| 2023 | 46 | 4,434 | 56% |
| 2024 | 52 | 4,366 | 58% |
| 2025 from claims | – | 4,373 4,013–4,627 | 59% |
| 2026 forecast | – | 4,473 3,936–5,162 | 59% |
| 2027 forecast | – | 4,511 3,856–5,375 | 59% |
| 2028 forecast | – | 4,548 3,795–5,568 | 60% |
| 2029 forecast | – | 4,584 3,744–5,749 | 60% |
| 2030 forecast | – | 4,620 3,701–5,921 | 61% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 37% of the cases CMS names in Pennsylvania; 37 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 2% inpatient hospital, 88% hospital outpatient, 6% surgery center, 4% office. The share outside the hospital has moved −7 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.7 | 30% | 6,960 in 2030+2.2%/yr |
| Massachusetts | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.6 | 17% | 3,720 in 2030+2.6%/yr |
| New Jersey | 25 | 2,622+0.6%/yr | +0.6%/yr | 2.7 | 20% | 3,090 in 2030+2.8%/yr |
| Connecticut | 9 | 999−0.1%/yr | −0.1%/yr | 3.3 | 8% | 1,420 in 2030+6%/yr |
| New Hampshire | 3 | 531−0.4%/yr | −0.4%/yr | 2.5 | 6% | 910 in 2030+9.3%/yr |
| Rhode Island | 6 | 346−0.6%/yr | −0.6%/yr | 4.2 | 0% | 430 in 2030+3.6%/yr |
| Maine | 3 | 290−6%/yr | −6%/yr | 2.0 | 7% | 370 in 2030+4%/yr |
| Vermont | 4 | 193−5.7%/yr | −5.7%/yr | 1.8 | 9% | 360 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 164 | 6,776−2%/yr | −2%/yr | 5.00.9× | 12% | 6,810 in 2030+0.1%/yr |
| BPH procedures | 78 | 5,698−7.3%/yr | −7.3%/yr | 4.21.0× | 31% | 4,890 in 2030−2.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.11.2× | 8% | 3,450 in 2030+2.8%/yr |
| Prostatectomy & nephrectomy | 27 | 1,659−0.2%/yr | −0.2%/yr | 1.31.2× | 0% | 1,900 in 2030+2.3%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Femselect leads with 51% of company spending on these surgeons in 2025, −15 pts on 2024.
In 2025, 9 companies reported engagement with Pennsylvania’s surgeons worth $39K in consulting, speaking, meals and travel tied to these products, about $744 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.